[Effect on animal tumors and toxicity of lycobetaine acetate (author's transl)].
@article{Zhang1981EffectOA, title={[Effect on animal tumors and toxicity of lycobetaine acetate (author's transl)].}, author={S. Zhang and F. Lu and J. L. Yang and L. Wang and B. Xu}, journal={Zhongguo yao li xue bao = Acta pharmacologica Sinica}, year={1981}, volume={2 1}, pages={ 41-5 } }
Lycobetaine, a derivative of lycorine, is a new type of antitumor drug. When lycobetaine acetate (AT-1840) was given ip to mice and rats inoculated with Ehrlich ascites carcinoma, ascites hepatoma, leukemia L-1210, leukemia P-388, Lewis lung cardinoma or Yoshida ascites sarcoma, the survival times of the tumor-bearing animals were prolonged significantly. Lycorine exhibited only negligible effect on the above-mentioned tumors.
The acute ip LD50 of AT-1840 in mice was 72 mg/kg. In dogs iv 3 or… CONTINUE READING
Topics from this paper
5 Citations
Lycobetaine acts as a selective topoisomerase IIβ poison and inhibits the growth of human tumour cells
- Biology, Medicine
- British Journal of Cancer
- 2001
- 38
- PDF
Synthesis, topoisomerase-targeting activity and growth inhibition of lycobetaine analogs.
- Chemistry, Medicine
- Bioorganic & medicinal chemistry
- 2013
- 24
Nanoemulsion loaded with lycobetaine–oleic acid ionic complex: physicochemical characteristics, in vitro, in vivo evaluation, and antitumor activity
- Materials Science, Medicine
- International journal of nanomedicine
- 2013
- 31
- PDF